• FirefoxUpgrade to the new Firefox »
  •  Dow Up1.31% Nasdaq Up0.98%

    More On DND.TO



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Cipher Pharmaceuticals Inc. (DND.TO)

    14.89 Down 0.64(4.12%) Nov 24
    Add to Portfolio
    ProfileGet Profile for:
    Cipher Pharmaceuticals Inc.
    5650 Tomken Road
    Unit 16
    Mississauga, ON L4W 4P1
    Canada - Map
    Phone: 905-602-5840
    Fax: 905-602-0628
    Website: http://www.cipherpharma.com

    Index Membership:N/A
    Industry:Drugs - Generic
    Full Time Employees:N/A

    Business Summary 

    Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company that commercializes novel formulations of marketed molecules. The company focuses on in-licensing differentiated products, advancing them through the clinical development and regulatory approval stages, and either out-licensing to marketing partners or, in the case of the Canadian market, the company may market the product. Its products include a fenofibrate formulation marketed in the United States as Lipofen; an extended-release tramadol, which is marketed in the United States as ConZip and in Canada as Durela; and a novel formulation of the acne treatment isotretinoin, which is marketed in the United States as Absorica and in Canada as Epuris. The company also has the exclusive Canadian rights to market the Betesil Patch, a medicated plaster for the treatment of inflammatory skin conditions, such as plaque psoriasis. It has a collaborative partnership with Galephar Pharmaceutical Research, Inc. Cipher Pharmaceuticals Inc. was founded in 2000 and is based in Mississauga, Canada.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Cipher Pharmaceuticals Inc.

    Key Executives 
    Mr. Norman Evans CA, 60
    Chief Financial Officer and Sec.
    Ms. Joan Chypyha ,
    VP of Marketing and Sales
    Mr. Shawn Patrick O'Brien ,
    Chief Exec. Officer and Pres
    Ms. Linda Angaritis ,
    VP of Global Regulatory Compliance & Quality
    Mr. Peter Weiler ,
    VP of Bus. Devel.
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in CAD.